RS BioTherapeutics
Overview
RS BioTherapeutics is a life sciences company focused on developing innovative therapies for pulmonary diseases characterized by inflammation. Founded in 2021 and based in Cumberland, Maryland, the company aims to harness the therapeutic power of cannabinoids. Its first investigational compound, RSBT-001, is a semi-synthetic cannabidiolic acid complex in development for treating conditions such as Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). The company has raised approximately $5.7 million in funding and is co-directed by a team of experts in biopharma and cannabinoid science.
Recent Developments
- November 2024: RS BioTherapeutics participated in the Respiratory Innovation Summit organized by the American Thoracic Society. This assembly brings together leaders in respiratory innovation from academic, clinical, and business spheres to promote new treatments for pulmonary diseases. The attendance at the event was higher than previous years, signifying growing interest in respiratory therapeutics.
- July 2024: The company announced a research collaboration with the University of Colorado School of Medicine. This partnership focuses on assessing RSBT-001’s application in treating severe lung diseases and potential use as a chemical countermeasure.
- April 2024: RS BioTherapeutics launched a crowdfunding campaign through StartEngine, allowing public investment and collaboration in their research initiatives. This move intends to broaden their investor base to include individual contributors interested in medical innovation.
- February 2024: RS BioTherapeutics established a Therapeutic Expert Council comprising renowned pulmonary experts to provide insights on the development of RSBT-001.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2021 |
| Headquarters | Cumberland, Maryland, USA |
| Founders | Information not publicly specified |
| Revenue | Information not publicly specified |
| Profits | Information not publicly specified |
| Key Investors | Synthonics, various private investors |
| Industry | Drug Discovery, Biopharmaceuticals |
| Number of Employees | 6 |
Early History
RS BioTherapeutics was established with the intent to bring cannabinoid-based therapies to the forefront of respiratory disease treatment. With chronic pulmonary diseases affecting millions globally, the company identified a critical need for steroid-free alternatives. Its foundational ethos was cemented through the development of RSBT-001, targeting pulmonary inflammation. In partnering with Synthonics, a leader in metal coordination chemistry, RS BioTherapeutics saw significant milestones including a provisional patent application for a unique cannabis cultivar, driving innovation in therapeutic cannabinoid production.
Company Profile and Achievements
The business model of RS BioTherapeutics focuses on drug discovery and development in the field of cannabinoid-based therapies for lung diseases. A significant achievement in its journey was the development and trial of RSBT-001, a semi-synthetic compound. The company's strategic initiatives have also included securing collaborations with institutions like the NIH and the University of Colorado, indicating a robust commitment to clinical validation and potential market entry. Its establishment of the Therapeutic Expert Council highlights its emphasis on scientific rigor and specialist engagement in crafting therapeutic avenues for diseases such as COPD and IPF.
Notable Milestones:
- Acquisition of a unique cannabis cultivar for therapeutic research.
- Establishment of research collaborations with government and academic entities.
- Development of RSBT-001 as an alternative treatment for harmful inflammations in respiratory conditions.
Current Operations and Market Position
RS BioTherapeutics is concentrated on the clinical development of RSBT-001 and its commercialization. As it advances toward an Investigational New Drug application, the company is poised within the broader biopharmaceutical sector and cannabis-based drug discovery niche. Its competitive advantage lies in its novel use of cannabinoid science to address inflammation without the side effects typically associated with corticosteroids. The company continues to target initiative investments, evidenced by its early-stage VC funding and strategic crowdfund efforts, aiming to expand its impact and ensure the practical application of its therapies.
Related Topics
RS BioTherapeutics and NIH Collaboration: Emphasizes the ongoing partnership with NIH to evaluate RSBT-001, showcasing its potential to meet critical needs in pulmonary inflammation treatment.
RS BioTherapeutics Research and Development: Details the company's active pipeline and innovative work in advancing cannabinoid-based solutions for pulmonary health.
Conclusion
RS BioTherapeutics is carving a niche in cannabinoid-based drug development, particularly in the challenging field of respiratory diseases. The company’s establishment of highly strategic collaborations and its focus on steroid-free, inflammation-targeted therapies represent significant strides toward addressing unmet needs in healthcare. As it approaches critical IND filings and intensifies development initiatives, RS BioTherapeutics is well-positioned to be a key player in transforming treatment paradigms for respiratory conditions, with potential broader implications for cannabinoid applications in medicine.